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Esperanza B. Papadopoulos,1,4 Andromachi Scaradavou,2 James W. Young,1,4
Marcel R. M. van den Brink1,4Allogeneic transplant access can be severely limited for patients of racial and ethnic minorities without suit-
able sibling donors. Whether cord blood (CB) transplantation can extend transplant access because of the
reduced stringency of required HLA-match is not proven. We prospectively evaluated availability of unre-
lated donors (URD) and CB according to patient ancestry in 553 patients without suitable sibling donors.
URDs had priority if adequate donors were available. Otherwise$4/6 HLA-matched CB grafts were chosen
utilizing double units to augment graft dose. Patients had highly diverse ancestries including 35% non-
Europeans. In 525 patients undergoing combined searches, 10/10 HLA-matched URDs were identified in
53% of those with European ancestry, but only 21% of patients with non-European origins (P\.001). How-
ever, the majority of both groups had 5-6/6 CB units. The 269 URD transplant recipients were predominantly
European, with non-European patients accounting for only 23%. By contrast, 56% of CB transplant recipients
had non-European ancestries (P\.001). Of 26 patients without any suitable stem cell source, 73% had non-
European ancestries (P\.001). Their median weight was significantly higher than CB transplant recipients
(P \.001), partially accounting for their lack of a CB graft. Availability of CB significantly extends
allo-transplant access, especially in non-European patients, and has the greatest potential to provide a suitable
stem cell source regardless of race or ethnicity. Minority patients in need of allografts, but without suitable
matched sibling donors, should be referred for combined URD and CB searches to optimize transplant
access.
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Allogeneic hematopoietic stem cell transplantation
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6/j.bbmt.2010.08.011achievements of modern hematology [1]. It is therefore
imperative that all eligible patients have equal access
to this therapy. However,\30% of patients requiring
an allograft have a suitable human leukocyte antigen
(HLA)-matched sibling donor [1]. Although unrelated
donor (URD) registries can supply grafts for those
without a suitable sibling donor, the strict HLA-
match needed to minimize the chance of lethal or
debilitating transplant complications limits the donor
pool [2,3]. Patients of racial and ethnic minorities
are disadvantaged because of their relatively low
numbers in volunteer registries and an increased
likelihood that potential donors will be unavailable
upon request [4-6]. Highly polymorphic HLA loci
pose additional challenges in some groups, such as
patients of African ancestry [4].
In 1989, Gluckman and colleagues [7] reported
the use of HLA-identical sibling donor cord blood
(CB) as a stem cell source for transplantation.1541
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lated donor CB transplantation [8-13], including
leukemia-free survival at least comparable to that pro-
vided by 8/8 HLA-matched URD bone marrow trans-
plantation in children [14]. Promising survival has also
been reported in adults [15-17], with 2 recent reports
suggesting double-unit CB transplantation may be
associated with comparable survival to that of HLA-
matched sibling donor and URD transplantation in
patients with hematologic malignancies [18,19]. A
remarkable feature of this neonatal stem cell source is
a greatly reduced incidence of graft-versus-host disease
(GVHD) for the degree of donor-recipient HLA-
mismatch [8-13]. Therefore, public CB banking was
originally proposed as a means to provide a stem cell
source that could extend transplant access [20]. That
CB can extend transplant access to minorities has been
suggested, but this hypothesis has never been formally
tested and cannot be assumed given the relatively small
size of the global CB inventory [21]. Hence, we con-
ducted a prospective study evaluating donor availability
according to patient ancestry in the highly diverse
population referred to our Center in New York City.PATIENTS AND METHODS
Study Population
Patients were candidates for allogeneic hemato-
poietic stem cell transplantation for the treatment of
high-risk hematologic malignancies or severe aplastic
anemia. They had no suitable HLA-matched related
donors, were eligible for either URD or CB transplan-
tation, provided informed consent for a formal donor
search, and were transplanted or had their search
closed during the study period. Institutional review
board approval was obtained to analyze patient data in-
cluding those patients whose preliminary search failed
to identify any potentially suitable URDor CB units to
request for typing. Adopted patients with unknown an-
cestry, patients whose searches were ongoing without
a donor chosen, and searches for second transplants
were excluded. Data on the searches for 553 patients
were collected prospectively between October 1,
2005, and December 31, 2009.URD and CB Searches
The majority of patients underwent combined
search for both URD and CB units. URD searches
and grafts were facilitated by the National MarrowDo-
nor Program (NMDP). CB searches were conducted
through the Bone Marrow Donors Worldwide, the
NMDP, and the New York Blood Center (NYBC),
and both domestic and international units were consid-
ered for potential use. Memorial Sloan-Kettering
Cancer Center (MSKCC) policy is to type potentialURD recipients and their donors at 10 HLA-alleles
given the progressive decrease in survival with an allele
or antigen mismatch at each of the HLA-A,-B,-C, and
-DRB1 loci when transplanting URD grafts, and that
HLA-DQ mismatches are detrimental when present
with other mismatches [2,3]. Further, our institution is
investigating T cell depletion as a means to abrogate
severe graft-versus-host disease (GVHD), especially if
mismatched. Therefore, adequate donor-recipient
HLA-match was defined as $8/10 HLA-A, -B, -C,
-DRB1, or -DQ for a T cell-depleted graft. Patients re-
quiring unmodified grafts in the setting of very high risk
disease or reduced-intensity conditioning (RIC) re-
quired $9/10 HLA-match for an unmodified URD
graft in order to reduce the risk of life-threatening
GVHD.
By contrast, adequate CB units were$4/6HLA-A,
-B antigen, or -DRB1 allele matched to the recipient
with a cryopreserved total nucleated cell (TNC) dose
$1.5  107/kg/unit. Double-unit grafts were used to
augment engraftment, reduce treatment-related mor-
tality, potentially reduce relapse [22,23], and improve
survival in all patients [15-17]. Unit-unit HLA-match
was not considered. CB transplant recipients prefera-
bly had at least 1 additional backup unit identified
before transplant. URDs had priority as the stem cell
source. CB was chosen if no suitably HLA-matched
URDs were available within the required time period
according to physician assessment of transplant
urgency. Patients were transplanted with high-dose
or RIC according to age, diagnosis, prior therapy,
and comorbidities.Assessment of Patient Ancestry
Patient ancestry informationwas collected by physi-
cians and transplant coordinators using direct patient
interview to determine the country of birth of the
patient, each parent, and each grandparent for as many
generations as known or needed to establish the
ancestry. In addition, patients self-identified themselves
as Black and/or Hispanic.We used similar categories as
previous reports [4,24], but additionally divided patients
of European ancestry, however, into northwestern,
eastern, southern, and mixed Europeans. Moreover,
non-European ancestries were divided into Asian, Afri-
can (Hispanic and non-Hispanic), White Hispanic,
Middle Eastern, and mixed non-European groups. Pa-
tients of African ancestry included African-Americans,
and immigrants from Africa or the Caribbean. Non-
Europeanmixes included any patientwith at least partial
non-European origins even if partly European (but
excluded those who self-identified as Black), and fre-
quently included complex racial mixes. Information
concerning the ancestry or race of URDs and maternal
donors of CB was incomplete, precluding analyses of
recipient-donor ancestral matching.
Table 1. Formal Search Results Showing the Best HLA-Matched URD or Best CB Units in Patients who Underwent Combined
Searches (n 5 525): URD Predominantly Serves Patients of Northwestern, Eastern, or Mixed European Ancestry, Whereas CB
Extended Access to a Stem Cell Source to Both Europeans and Non-Europeans
Patients of European Ancestries
Northwestern European
(n 5 104)
Eastern European
(n 5 76)
Southern European
(n 5 60)
European Mix
(n 5 101)
Best URD
10/10 64 (62%) 45 (59%) 20 (33%) 51 (50%)
9/10 28 (27%) 20 (26%) 20 (33%) 31 (31%)
#8/10 12 (12%) 11 (14%) 20 (33%) 19 (19%)
Best CB*
5-6/6 88 (85%) 62 (82%) 36 (60%) 84 (83%)
4/6 15 (14%) 12 (16%) 15 (25%) 14 (14%)
No CB 1 (1%) 2 (3%) 9 (15%) 3 (3%)
Patients of Non-European Ancestries
Asian
(n 5 42)
African
(n 5 61)
White Hispanic
(n 5 48)
Middle Eastern
(n 5 10)
Non-European Mix
(n 5 23)
Best URD
10/10 8 (19%) 5 (8%) 10 (21%) 6 (60%) 9 (39%)
9/10 6 (14%) 20 (33%) 14 (29%) 1 (10%) 8 (35%)
#8/10 28 (67%) 36 (59%) 24 (50%) 3 (30%) 6 (26%)
Best CB*
5-6/6 36 (86%) 35 (57%) 33 (69%) 8 (80%) 19 (83%)
4/6 6 (14%) 14 (23%) 10 (21%) 2 (20%) 2 (9%)
No CB 0 12 (20%) 5 (10%) 0 2 (9%)
URD indicates adult unrelated volunteer donor; CB, cord blood.
*Best CB units were defined according to HLA-match but also had to have an adequate total nucleated cell (TNC) dose of at least 1.5  107/kg/unit.
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Tests of association between independent binary
variables were performed using Fisher’s exact test; the
paired binary data were examined using McNemar’s
test. For continuous variables, the test of equality be-
tween independent groups was based on theWilcoxon
rank sum test. For multiple observations per subject,
the Wilcoxon test incorporating clustering was em-
ployed. The time to secure an URD versus a CB graft
was not analyzed as URD were given priority, and
therefore, URD and CB were not given equal weight
at the search initiation. Also, it is already established
that cryopreserved CB is available more quickly than
URD [25].RESULTS
Patient Ancestry and Demographics
Our patients had highly diverse ancestries. Only
112 (20%) of the 553 patients were of northwestern
European ancestry, whereas 81 (15%) had eastern, 60
(11%) southern, and 105 (19%) mixed European
backgrounds. Northwestern Europeans were predomi-
nantly ofEnglish, Irish, Scottish,German, and/orScan-
dinavian origins. The majority of southern Europeans
originated from southern Italy. European mixes were
most frequently a mix of northwestern and southern
European (eg, Sicilian Italian-Irish), or northwesternand eastern European (eg, English-Polish) ancestries.
Of the 195 (35%) patients of non-European origins,
46 (8%) had Asian, 64 (12%) African (55 non-
Hispanic and 9 Hispanic), 51 (9%) White Hispanic,
11 (2%) Middle Eastern, and 23 (4%) mixed non-
European ancestries. There were no Pacific Islanders.
Ten of the mixed non-Europeans had part Native
American ancestry, however. The majority of patients
(n5 445, 80%) were born in the United States.
Patients had amedian age of 47 years (range: 0.9-73
years). Diagnoses included acute leukemia (n 5 294;
53%), myelodysplastic syndrome/myeloproliferative
disorders (n 5 83; 15%), non-Hodgkin lymphoma or
chronic lymphocytic/prolymphocytic leukemia (n 5
119; 22%), Hodgkin lymphoma (n5 36; 7%), multiple
myeloma (n5 12; 2%), aplastic anemia (n5 7; 1%), or
other malignancies (n5 2;\1%).Results of Combined URD and CB Searches
Nearly all patients (n 5 525, 95%) had combined
URD andCB formal searches that allowed direct com-
parison of the best matched URD, and best matched
and adequately dosed CB units, identified for the
same patients (Table 1). The remaining 28 patients
had suitably matched URDs and a CB search was not
performed. We found that fully matched (10/10)
URD were identified for the majority of those with
northwestern (62%) or eastern European (59%) back-
grounds, and half of those with mixed European
Table 2. Summary Comparison of URD and CB Availability
for Patients Undergoing Combined Searches According to
European versus Non-European Ancestry: European Patients
were Much More Likely to Secure a 10/10 HLA-Matched URD
Than Non-Europeans, Whereas 5-6/6 CB Were Available for
Both Groups
Europeans
(n 5 341)
Non-Europeans
(n 5 184) P
Best URD
10/10 (n 5 218) 180 (53%) 38 (21%) <.001
9/10 (n5148) 99 (29%) 49 (27%)
#8/10 (n 5 159) 62 (18%) 97 (53%)
Best CB
5-6/6 (n 5 401) 270 (79%) 131 (71%)
6/6 74 13
5/6 196 118
4/6 (n 5 90) 56 (16%) 34 (18%)
No CB (n 5 34) 15 (4%) 19 (10%)
URD indicates adult unrelated volunteer donor; CB, cord blood.
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URD was identified in only 33% of southern Euro-
pean patients (P 5 .001). Furthermore, although
60% of patients with Middle Eastern ancestry had
10/10 HLA-matched URD identified, this was only
the case for 19% of Asian, 8% of African, and 21%
of White Hispanic patients. By contrast, CB extended
stem cell availability to patients of both European and
non-European origins.
Overall, the difference in URD and CB availability
according to European versus non-European ancestry
in patients undergoing combined searches is summa-
rized in Table 2. European ancestry patients were
more likely to have a fully matched URD identified
than those of non-European origins (53% versus
21%, P \.001). In addition, Europeans were more
likely to have 5-6/6HLA-matched CB units (identified
in 79%) than to have 10/10 HLA-matched URD
(identified in 53%, P \.001). In non-European
patients, CB units matched at 5-6/6 HLA loci were
also more frequently identified than fully matched
URDs (71% versus 21%, P\.001).Table 3. Ancestral Composition of URD and CB Transplant
Recipients or Those Without a Suitable Graft: URD Trans-
plantation Predominantly Serves Europeans, Whereas CB
Extends Transplant Access to Patients of Non-European
Ancestry
Patient Ancestry
(Total 5 385)
URD Transplants
(n 5 269)
CB Transplants
(n 5 90)
No Graft
(n 5 26)
Europeans (n 5 255) 208 (77%) 40 (44%) 7 (27%)
Northwestern (n 5 79) 72 6 1
Eastern (n 5 57) 48 9 0
Southern (n 5 40) 26 10 4
Mix (n 5 79) 62 15 2
Non-Europeans (n 5 130) 61 (23%) 50 (56%) 19 (73%)
Asian (n 5 30) 13 17 0
African (n 5 50) 22 15 13
White Hispanic (n 5 29) 15 10 4
Middle Eastern (n 5 8) 5 3 0
Non-European
Mix (n 5 13)
6 5 2
URD indicates adult unrelated volunteer donor; CB, cord blood.Transplant Analysis
Of the 553 study population, 359 (65%) underwent
transplantation. Three-quarters (n 5 269, 75%) used
URDs (median age 48 years, range: 1-73 years),
whereas 25% (n 5 90) required CB (median age 37
years, range: 1-68 years). Twenty-six patients (5% of
the total study population) were not transplanted
specifically because of a lack of a suitable URD or
CB graft. The remaining 168 patients (30% of the
total) were not transplanted withURDor CB for other
reasons, predominantly because of refractory disease
or treatment complications (n 5 110). The propor-
tions of patients of European (n 5 103, 29%) and
non-European (n 5 65, 33%) backgrounds that could
not be transplanted for reasons other than not having
a graft were similar (P 5 .240).
URD Transplant Recipients
Notably, URD transplant recipients were predom-
inantly European (n 5 208, 77%), with the largest
subgroup having northwestern European ancestry
(Table 3 and Figures 1 and 2). Non-European patients
combined (n5 61) comprised only 23%ofURD trans-
plants. The majority (n 5 163, 61%) of the 269 URD
transplant recipients received 10/10 HLA-matched
grafts, whereas 81 (30%) received 9/10, and 25 (9%)
received 8/10 HLA-matched grafts. The percentage
of north-western Europeans that received 10/10
URD grafts (n5 49, 68%) was similar to that of other
Europeans (n 5 87, 64%, P 5 .646), but significantly
higher than non-Europeans (n 5 27, 44%, P 5 .008).
Among non-European patients, although 9 (69%)
Asian patients received 10/10 URD, this was only the
case in 3 (14%) African, and 6 (40%) white Hispanic
patients. URD grafts were obtained from North
America (n 5 175, 65%), Europe (n 5 74, 28%), and
elsewhere (n 5 20, 7%), with no relationship between
patient ancestry and need for a non-American donor.
CB Transplant Recipients
In marked contrast to URD transplant recipients,
only 6 (7%) CB transplant recipients had north-
western European ancestry. Notably, over half (n 5
50, 56%) of the CB recipients had non-European
origins, and included 19% Asian, 17% African, 11%
White Hispanic, 3% Middle Eastern, and 6% non-
European mix patients (Table 3 and Figures 1 and 2).
Thus, compared to URD transplants, CB transplant
recipients were more likely to have non-European
origins (56% versus 23%, P\.001). The majority of
CB transplant recipients received CB because they
did not have any suitable URDs. Of patients eligible
for transplant (ie, those in Table 3 that excludes those
not able to be transplanted because of refractory disease
or treatment complications), the availability of CB
extended transplant access to 8% of northwestern
Figure 1. Comparison of ancestry composition of URD and CB transplant recipients and those without a graft. Greater than 50% of CB transplant
recipients were non-European. Patients with African ancestry were the least likely to secure a suitable graft.
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European, and 19% of mixed European patients. For
patients of non-European ancestry, the availability of
CB had a greater impact by extending access to 57%
of Asian, 30% of African, 34% of white Hispanic,
38% of Middle Eastern, and 38% of mixed non-
European patients.Units were obtained from domestic
(n 5 129, 72%) or international (n 5 51, 28%) banks,
with no relationship between European versus non-
European ancestry and need for international units.
The median infused TNC doses of the double unit
grafts were 2.56 x 107/kg (range: 1.42-12.79) for the
larger and 1.94  107/kg (range: 0.91-7.09) for the
smaller unit. To compare the TNC doses available
to patients according to ancestry but independent
of the patient’s weight, the TNC/kg were back-Figure 2. Comparison of transplant type or lack of graft for individual
ancestry groups. URD transplantation predominantly serves Europeans.
CB significantly extends transplant access to patients of eastern, south-
ern, and mixed European ancestry, as well as Asian, African, white His-
panic, and mixed non-European patients.calculated to give the total TNC/unit. We found
European patients received units with a higher median
total TNC postthaw of 1.60  109/unit (range: 0.64-
2.97). This compared with 1.40  109/unit (range:
0.49-4.07) in non-European patients (P 5 .018).
The donor-recipient HLA-match of the 90 CB
grafts (180 units) was 5-6/6 in 58% (n 5 105), and 4/
6 in 42% (n 5 75). European patients were not more
likely to receive 5-6/6 HLA-matched units. Fifty
(63%) of 80 units European patients received, and 55
(55%) of 90 units given to non-European patients,
were 5-6/6 HLA-matched (P 5 .362).
Patients without URD or CB Grafts
Of the 26patients (median age 51 years, range: 14-68
years) not transplanted because of lack of any stem cell
source, most (n 5 19, 73%) had non-European origins
(P\.001), with 50% of these patients having African an-
cestry (Table 3 and Figures 1 and 2). Of the total study
population, 1 of 112 (\1%) northwestern, 0 of 81
(0%) eastern, 4 of 60 (7%) southern, and 2 of 105
(2%) mixed European patients had no graft. This
compared with 0 of 46 (0%) Asian, 13 of 64 (20%)
African, 4 of 51 (8%) White Hispanic, and 2 of 23
(9%) mixed non-European background patients.
Thus, patients of African ancestry had the greatest
difficulty securing an adequate URD or CB graft.
Notably, the median 82-kg (range: 50-151) weight of
‘‘no-graft’’ patients was higher than the 66 kg (range:
7-119) of CB transplant recipients (P\.001).DISCUSSION
New York City (NYC) has 1 of the most diverse
populations in the world. For example, in the Borough
1546 Biol Blood Marrow Transplant 16:1541-1548, 2010J. N. Barker et al.of Queens alone an estimated 170 foreign languages
are spoken [26]. The NYC population, therefore, gen-
erates patients with highly diverse ancestry and thus
varying and unique racial [4,27] and ancestral [28]
HLA haplotypes. This has allowed our Center to
directly compare the ability of the global inventory
of URDs and CB units to provide suitable grafts to
a variety of European, Asian, African, and White
Hispanic patients. To study donor availability, we
used similar ancestry categories as previous reports
[4,24], but distinguished European subgroups,
African Hispanics from White Hispanics, and non-
European mixes. This considerably broadens the
reporting of patient origins beyond ‘‘White’’ versus
‘‘non-White.’’ Although the attribution of ancestry
remains complex, our study has the advantage that
our physicians and dedicated transplant coordinators
took a personal family history of the birthplace of the
patients and their ancestors rather than relying on staff
assessment of presumed race or ethnicity.
We demonstrate that despite the 6.7 million
URDs registered with the NMDP, and an additional
5 million donors in affiliated registries worldwide
[29], URD transplantation predominantly serves
patients of northwestern, eastern, and mixed Euro-
pean ancestry. However, southern European, Asian,
African, White Hispanic, and mixed non-European
patients were much less likely to secure a suitable
URD. These groups together constituted 46% of
our patients. Furthermore, patients of non-European
backgrounds, especially African ancestries, were more
likely to receive a mismatched URD transplant, with
a higher chance of compromising transplant outcome
[2,3]. We, therefore, show that URD registries
predominantly serve patients of European origins, with
the exception of southern Europeans, and confirm the
suggestion of the 2002 General Accounting Office
Report to the U.S. Congress that ‘‘equal access to
a match may not be attainable’’ according to race.
From a practical standpoint our findings demonstrate
that transplant centers should be mindful of the
patient’s ancestry during URD searches given the
decreased likelihood of search success for patients with
southern European and non-European origins.
CB can be available substantially faster than URDs
[25], an advantage for patients requiring urgent
transplantation. We now show for the first time that,
because of the relative tolerance of HLA-disparity,
CB has a further advantage: despite a relatively small
global inventory of approximately 400,000 public units
[21], CB significantly extends transplant access to all
patients, especially those of southern European and
non-European ancestry. This is in marked contrast
to URD transplantation, and is despite the median
weight of 66 kg (range: 7-119) in our CB transplant
recipients. Because of the addition of CB as an alterna-
tive stem cell source, only 5% of our diverse patientpopulation undergoing URD searches could not be
transplanted because of lack of a graft. Furthermore,
given that approximately one-quarter of allograft
referrals have a sibling donor, the addition of CB to
volunteer donors means that the lack of a suitable
stem cell source is now a rare barrier to transplant.
An additional finding at the opposite end of the donor
availability spectrum is striking: Europeans who had
10/10 HLA-matched URD were even more likely to
have 5-6/6 HLA-matched CB units, with 22% of
European patients having 6/6 HLA-matched CB
units, for example. This is relevant given the reporting
of higher leukemia-free survival after 6/6 HLA-
matched CB transplantation compared with 8/8 HLA-
allele matched URD bone marrow transplantation in
children [14]. Thus, a randomized study between
5-6/6 matched CB and 10/10 URD may be feasible
in the future.
However, despite an encouraging extension of
access, CB had limitations. Independent of recipient
weight, patients of non-European origins were more
likely to receive units with a lower TNC dose. Further,
although no Asian patient lacked a suitable CB graft,
one-fifth of African ancestry patients, and a significant
numberof patientswith southernEuropean,WhiteHis-
panic, andmixed non-European ancestries, did not have
suitable CB units. These groups likely have a lesser rep-
resentation in the global CB inventory. Such patients,
especially those with an adult weight, are less likely to
identify an adequately HLA-matched and dosed CB
graft, evenwhenutilizingdoubleunits.Therefore, based
on these findings, prior reports suggesting that only
a small inventory of CB units should be adequate
[30,31] are not correct. An increased inventory of
adequately dosed and high-quality units from racially
diverse populations is required to rectify this inequity.
Units collected from African births have lower TNC
counts [32], contributing to a lower inventory of ade-
quately dosed units for African ancestry patients. This
is a particular challenge that must be addressed.
We can now demonstrate that CB is extending
transplant access to racial and ethnic minorities. Given
the recent promising survival after pediatric and adult
CB transplantation for hematologic malignancies, this
is a major advance in the field. It is known that increas-
ing URD registry size will not result in an appreciable
increase in donor availability for populations such as
African-Americans because of their varied genetic
composition [4,6]. Extending search time also does
not increase the likelihood of securing a suitable
donor [33]. Our study suggests that with adequate
funding, CB has the greatest chance of providing
a stem cell source regardless of race or ethnicity.
This is compelling support for increased funding of
public CB banks and should prompt studies to estimate
the size of the CB inventory needed to provide stem
cells to all. Furthermore, patients from racial and
Biol Blood Marrow Transplant 16:1541-1548, 2010 1547Transplant Access in Racial and Ethnic Minoritiesethnic minorities in need of allografts, but without
suitable matched sibling donors, should be promptly
referred for combined URD and CB searches to
optimize identification of a suitable donor and timely
transplantation.ACKNOWLEDGMENTS
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